US adjusts thyroid medication policies
Vitruvias Therapeutics, an American company, announced the withdrawal of a batch of 30 mg thyroid medication tablets due to the potential presence of higher-than-expected potency, which could cause hyperthyroidism. It is noted that this situation may lead to symptoms such as weight loss, nervousness, high blood pressure, and rapid heartbeat, especially among the elderly, pregnant women, and infants. The company has not received any reports of adverse events so far. Patients taking the affected batch are advised not to stop using the medication on their own and to contact their healthcare provider for guidance on alternative treatment options.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)